URIST MARSHALL (EVP & Co-Head Research & Inv.) sold 20.0% of their position (20K shares) of ROYALTY PHARMA PLC on the open market
Open‑market sale worth $769.6K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/6/2026ACC: 0001838139-26-000002
Officer· EVP & Co-Head Research & Inv.
Since Dec 2020
-20K
Net shares
Net seller
$769.6K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
20K disposed
Non-Derivative Transactions1
Class A Ordinary Shares
Indirect
Shares
−20K
Price / share
$38.48
Trade value
$769.65K
% of position
20.0%
1/2/2026
100K→80K
Total
Net shares
−20K
Net value
-$769.65K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary Shares Indirect | 1/2/2026 | S · Sale | −20K | $38.48 | $769.65K | 20.0% | 100K | 80K |
| Total | −20K | -$769.65K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Class A Ordinary Shares
IndirectShares owned19.02K
Class A Ordinary Shares
DirectShares owned7.40K
Total
7.40K direct·19.02K indirect26.42K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Ordinary Shares | 19.02K | Indirect |
| Class A Ordinary Shares | 7.40K | Direct |
| Total | 26.42K | 7.40K direct·19.02K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported